The written procedure, Gauge and Calibration Management, SOP 03-103, version 02, effective date 7/20/15, did not include adequate instructions regarding where a balance should be placed for weighing and measuring operations.
Inspection Record
Qingdao Kangyuan Pharmaceutical Co., LTD — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Th of the ater system is not monitored and now® are installed throughout the system.
On 4/18/16, we observed an electrical balance, 1D # SC- -|7-04, and a container housing a®® reference weight, 1D # SC-DZC-17-04, sitting on the floor ofthe arehouse@@ which may be subject to contamination and instability.
On 4/18/16, we observed an attachment form, titled “ Balance using records 03-103-A1 02”, which was used to record the weight of materials.@ lL) EE) Crude, on 4/2/16.
The scale, ID # SC-DZC-17-06, which is used in the oom, is@@ calibrated using amo standard weight weighing range is between 0) In addition the vendor calibration certificate dated id not indicate that the scale had been calibrated within the scale weighing range.
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.